{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:15:36Z","timestamp":1761513336460},"reference-count":48,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2013,8,19]],"date-time":"2013-08-19T00:00:00Z","timestamp":1376870400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0072251","type":"journal-article","created":{"date-parts":[[2013,8,19]],"date-time":"2013-08-19T21:07:29Z","timestamp":1376946449000},"page":"e72251","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":14,"title":["Predictive Value of XPD Polymorphisms on Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis"],"prefix":"10.1371","volume":"8","author":[{"given":"Mantang","family":"Qiu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingwen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangxiang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2013,8,19]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":"Cancer statistics, 2010","volume":"60","author":"A Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/(SICI)1097-0215(19990315)80:6<827::AID-IJC6>3.0.CO;2-P","article-title":"Estimates of the worldwide incidence of 25 major cancers in 1990","volume":"80","author":"DM Parkin","year":"1999","journal-title":"Int J Cancer"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1136\/bmj.311.7010.899","article-title":"Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials","volume":"311","year":"1995","journal-title":"BMJ"},{"key":"ref4","first-page":"1087","article-title":"New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions","volume":"4","author":"PA Bunn Jr","year":"1998","journal-title":"Clin Cancer Res"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1200\/JCO.2004.09.053","article-title":"American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003","volume":"22","author":"DG Pfister","year":"2004","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"548","DOI":"10.6004\/jnccn.2006.0046","article-title":"Non-small cell lung cancer clinical practice guidelines in oncology","volume":"4","author":"DS Ettinger","year":"2006","journal-title":"J Natl Compr Canc Netw"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3322\/canjclin.52.1.23","article-title":"Cancer statistics, 2002","volume":"52","author":"A Jemal","year":"2002","journal-title":"CA Cancer J Clin"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1054\/bjoc.2000.1740","article-title":"Meta-analysis of single agents in the chemotherapy of NSCLC: what do we want to know?","volume":"84","author":"A Bahl","year":"2001","journal-title":"Br J Cancer"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1093\/jnci\/94.14.1091","article-title":"An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer","volume":"94","author":"CH Bosken","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.2004.08.067","article-title":"XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy","volume":"22","author":"S Gurubhagavatula","year":"2004","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0305-7372(98)90056-1","article-title":"Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy","volume":"24","author":"E Reed","year":"1998","journal-title":"Cancer Treat Rev"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/carcin\/21.3.453","article-title":"Nucleotide excision repair and human syndromes","volume":"21","author":"J de Boer","year":"2000","journal-title":"Carcinogenesis"},{"key":"ref13","first-page":"5457","article-title":"Regulation of cisplatin resistance and homologous recombinational repair by the TFIIH subunit XPD","volume":"62","author":"R Aloyz","year":"2002","journal-title":"Cancer Res"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.7314\/APJCP.2012.13.6.2583","article-title":"Predictive role of ERCC1 and XPD genetic polymorphisms in survival of Chinese non-small cell lung cancer patients receiving chemotherapy","volume":"13","author":"ZY Zhang","year":"2012","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1097\/JTO.0b013e31824fe98c","article-title":"Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine\/platinum","volume":"7","author":"WY Liao","year":"2012","journal-title":"J Thorac Oncol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"e33200","DOI":"10.1371\/journal.pone.0033200","article-title":"Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patients","volume":"7","author":"W Wu","year":"2012","journal-title":"PLoS One"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s12094-012-0785-3","article-title":"Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients","volume":"14","author":"X Chen","year":"2012","journal-title":"Clin Transl Oncol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.lungcan.2010.10.011","article-title":"No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis","volume":"72","author":"M Yin","year":"2011","journal-title":"Lung Cancer"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"e38150","DOI":"10.1371\/journal.pone.0038150","article-title":"Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients","volume":"7","author":"JY Yin","year":"2012","journal-title":"PLoS One"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s12032-010-9443-1","article-title":"Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis","volume":"28","author":"SZ Wei","year":"2011","journal-title":"Med Oncol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"D Moher","year":"2009","journal-title":"PLoS Med"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"P Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"ref23","unstructured":"Wells G, Shea B, D. OC, Peterson J, Welch V, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised stud-ies in meta-analyses."},{"key":"ref24","doi-asserted-by":"crossref","first-page":"820","DOI":"10.7326\/0003-4819-127-9-199711010-00008","article-title":"Quantitative synthesis in systematic reviews","volume":"127","author":"J Lau","year":"1997","journal-title":"Ann Intern Med"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"M Egger","year":"1997","journal-title":"BMJ"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s00280-012-1985-9","article-title":"Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer","volume":"70","author":"M Provencio","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.lungcan.2012.07.009","article-title":"Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin","volume":"78","author":"M Tiseo","year":"2012","journal-title":"Lung Cancer"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1097\/JTO.0b013e3182307e1f","article-title":"Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin\/gemcitabine-treated advanced non-small cell lung cancer patients","volume":"6","author":"V Ludovini","year":"2011","journal-title":"J Thorac Oncol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1002\/cncr.26562","article-title":"Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study","volume":"118","author":"M Joerger","year":"2012","journal-title":"Cancer"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1007\/s12032-011-0033-7","article-title":"DNA repair gene polymorphism associated with sensitivity of lung cancer to therapy","volume":"29","author":"D Li","year":"2012","journal-title":"Med Oncol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.lungcan.2011.05.023","article-title":"Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy","volume":"75","author":"S Ren","year":"2012","journal-title":"Lung Cancer"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.lungcan.2010.11.004","article-title":"Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy","volume":"73","author":"L Liu","year":"2011","journal-title":"Lung Cancer"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.lungcan.2010.05.005","article-title":"Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine","volume":"71","author":"N Vinolas","year":"2011","journal-title":"Lung Cancer"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/COC.0b013e3181b9cedc","article-title":"Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer","volume":"33","author":"F Li","year":"2010","journal-title":"Am J Clin Oncol"},{"key":"ref35","first-page":"859","article-title":"Lack of influence of XRCC1 and XPD gene polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancers","volume":"10","author":"CY Yao","year":"2009","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1200\/JCO.2008.20.8793","article-title":"Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics","volume":"27","author":"DR Gandara","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3816\/CLC.2009.n.015","article-title":"DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer","volume":"10","author":"A Kalikaki","year":"2009","journal-title":"Clin Lung Cancer"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1158\/1078-0432.CCR-07-1364","article-title":"Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine\/cisplatin-treated advanced non-small cell lung cancer patients","volume":"14","author":"C Tibaldi","year":"2008","journal-title":"Clin Cancer Res"},{"key":"ref39","first-page":"196","article-title":"[XRCC1 and XPD genetic polymorphisms predict clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer]","volume":"28","author":"P Yuan","year":"2006","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/annonc\/mdj135","article-title":"Polymorphisms in DNA repair genes modulate survival in cisplatin\/gemcitabine-treated non-small-cell lung cancer patients","volume":"17","author":"R de las Penas","year":"2006","journal-title":"Ann Oncol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdh319","article-title":"Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer","volume":"15","author":"D Isla","year":"2004","journal-title":"Ann Oncol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.lungcan.2003.11.019","article-title":"Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy","volume":"44","author":"JS Ryu","year":"2004","journal-title":"Lung Cancer"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1289\/ehp.6632","article-title":"Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays","volume":"111","author":"WW Au","year":"2003","journal-title":"Environ Health Perspect"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Liu L, Wu J, Zhong R, Wu C, Zou L, <etal>et al<\/etal>.. (2012) Multi-loci analysis reveals the importance of genetic variations in sensitivity of platinum-based chemotherapy in non-small-cell lung cancer. Mol Carcinog.","DOI":"10.1002\/mc.21942"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1097\/JTO.0b013e3182272273","article-title":"Combined effect of genetic polymorphisms in P53, P73, and MDM2 on non-small cell lung cancer survival","volume":"6","author":"L Liu","year":"2011","journal-title":"J Thorac Oncol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"e62485","DOI":"10.1371\/journal.pone.0062485","article-title":"Replication study in Chinese population and meta-analysis supports association of the 5p15.33 locus with lung cancer","volume":"8","author":"J Ke","year":"2013","journal-title":"PLoS One"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.1002\/cncr.26154","article-title":"A functional polymorphism (\u22121607 1G\u2013&gt;2G) in the matrix metalloproteinase-1 promoter is associated with development and progression of lung cancer","volume":"117","author":"L Liu","year":"2011","journal-title":"Cancer"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1158\/1078-0432.CCR-11-1531","article-title":"Predictive value of XRCC1 gene polymorphisms on platinum-based chemotherapy in advanced non-small cell lung cancer patients: a systematic review and meta-analysis","volume":"18","author":"J Wu","year":"2012","journal-title":"Clin Cancer Res"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0072251","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T03:05:39Z","timestamp":1588993539000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0072251"}},"subtitle":[],"editor":[{"given":"Xiaoping","family":"Miao","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,8,19]]},"references-count":48,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2013,8,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0072251","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,19]]}}}